Last updated on August 2017

Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma


Brief description of study

This research study is studying a combination of two drugs as a possible treatment for Leptomeningeal Metastases from Melanoma. The names of the study interventions involved in this study are: - Ipilimumab - Nivolumab

Detailed Study Description

This research study is a Phase II clinical trial. Researchers hope to study the effects of the combination of Nivolumab and Ipilimumab. Many cancers use specific pathways (such as PD-1/PD-L1 and CTLA-4) to evade the body's immune system. Nivolumab and ipilimumab work by blocking the PD-1/PD-L1 and CTLA-4 pathways and thus releasing the brakes on the immune system so it can stop or slow cancer. The FDA (the U.S. Food and Drug Administration) has approved Nivolumab and Ipilimumab as a treatment option for melanoma, but has not approved them for use when cancer cells spread to the cerebrospinal fluid

Clinical Study Identifier: NCT02939300

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Priscilla Brastianos, MD

Massachusetts general Hospital
Boston, MA United States
  Connect »

Eudocia K Quant Lee, MD ...

Dana Farber Cancer Institute
Boston, MA United States
  Connect »